Clinical trials: FLU
2009 H1N1 Influenza Virus
Effects of Age on Response to the 2009 H1N1 Virus Vaccine
Unlike most influenza viruses, the 2009 H1N1 virus has affected people between 5 and 40 years old more often than people 60 years old or older.
- Trial name
- NCT01055184
- Testing
- 2009 H1N1 Virus Vaccine
- Where
- United States
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- University of Rochester
Avian Influenza, Influenza
Co-Administration of AS03 Adjuvanted A/H7N9 IIV With IIV4
This is a randomized, un-blinded, Phase II study in males and non-pregnant females, who are in good health, 19 to 64 years of age.
- Conditions
- Avian Influenza, Influenza, Influenza Immunisation
- Trial name
- NCT03318315
- Testing
- AS03, Inactivated influenza H7N9 vaccine, Influenza Virus Quadrivalent Inactivated Vaccine
- Where
- 4 sites in United States
- Volunteers
- 149 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Pain, Quality of Life
FLUAD® vs. Fluzone® High-Dose Study
The overall aim of the study is to compare safety and immunogenicity of inactivated influenza vaccine (IIV), adjuvanted (FLUAD®) versus High-Dose inactivated influenza (Fluzone® High-Dose) vaccine in persons ≥65 years (20% aged…
- Conditions
- Pain, Quality of Life, Injection Site Reaction, Side Effect of Drug
- Trial name
- NCT03183908
- Testing
- FLUAD®, Fluzone® High-Dose
- Where
- 4 sites in United States
- Volunteers
- 757 people, healthy volunteers welcome
- Sponsor
- Duke University
Influenza
Safety and Immunogenicity Testing of Influenza Vaccine in Healthy Children 2 Months and 6 Months of Age
Primary Objective: To describe the safety of the 2004-2005 pediatric formulation of the inactivated, split-virion influenza vaccine Fluzone®, given in the two-dose schedule (described in the package insert for vaccine-naïve young…
- Trial name
- NCT00858468
- Testing
- Influenza virus vaccine (2004-2005 Formulation)
- Where
- 8 sites in United States
- Volunteers
- 394 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Influenza
A Re-licensing Study to Assess the Efficacy of Inflexal V Formulated With WHO Recommended 2008/2009 Influenza Virus Strains for the Northern Hemisphere
A study to assess whether the Northern Hemisphere 2008/2009 season influenza vaccine Inflexal V fulfills the EMEA requirements for re-registration of influenza vaccines
- Trial name
- NCT01303510
- Testing
- Inflexal V
- Where
- Switzerland
- Volunteers
- 111 people, healthy volunteers welcome
- Sponsor
- Crucell Holland BV
Influenza, Influenza Vaccines
Safety Study of Pandemic Candidate Influenza Vaccines in the Elderly Population
Influenza pandemics are caused by viruses that possess an Hemagglutinin molecule to which most of the population lacks immunity.
- Trial name
- NCT00306995
- Testing
- SB218352_15, SB218352_8, SB218352_4
- Where
- 10 sites in Germany
- Volunteers
- 385 people
- Sponsor
- GlaxoSmithKline
Influenza, Swine-origin A/H1N1 Influenza
A Study of Different Formulations of an A/H1N1 Pandemic Vaccine in Healthy Adults and the Elderly
The purpose of the study is to evaluate different doses of the Influenza A/H1N1 pandemic vaccine. Primary Objectives: To describe the immunogenicity of the candidate vaccines after each injection.
- Trial name
- NCT00953524
- Testing
- Monovalent Subvirion A/H1N1 Influenza vaccine (7.5 µg of HA), Monovalent Subvirion A/H1N1 Influenza vaccine (15 µg of HA), Monovalent Subvirion A/H1N1 Influenza vaccine (30 µg of HA)
- Where
- 15 sites in United States
- Volunteers
- 849 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Influenza, SARS-CoV-2
A Clinical Study to Investigate the Safety and Immunogenicity in Relation to Product Attributes of mRNA-1083 (Severe Acute Respiratory Syndrome Coronavirus 2 [SARS-CoV-2] and Influenza Vaccine)
The purpose of this study is to evaluate the safety, reactogenicity, and immunogenicity in relation to the product attributes of mRNA-1083 vaccine when administered as a single intramuscular (IM) injection in adults ≥50 to <65…
- Trial name
- NCT06508320
- Testing
- mRNA-1083
- Where
- 17 sites in United States, Canada
- Volunteers
- 931 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
Influenza
Influenza Challenge Study to Determine the Optimal Infection Dose and Safety of a Recombinant H3N2 (A/Texas/71/2017 (H3N2, Clade 3C3a) Influenza Strain
An open-label, dose-ranging influenza challenge study in healthy adult volunteers to determine the optimal infection dose and safety of a recombinant H3N2 (A/Texas/ A/Texas/71/2017 (H3N2, clade 3C3a) influenza strain.
- Trial name
- NCT04978454
- Testing
- Influenza RG-A/Texas/71/2017 (H3N2) Challenge
- Where
- 2 sites in United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Infectious Disease, Pneumonia, Bacterial
Vaccination Education Through Pharmacists and Senior Centers (VEPSC)
The study consists of two arms (PHARM and PEER) designed to educate participants about three vaccine-preventable diseases (zoster, pneumonia, and influenza) and vaccination.
- Conditions
- Infectious Disease, Pneumonia, Bacterial, Influenza, Zoster; Herpes
- Trial name
- VEPSC (NCT03239665)
- Testing
- Pharmacist-led Intervention (PHARM), Peer-led Intervention (PEER)
- Where
- United States
- Volunteers
- 335 people, healthy volunteers welcome
- Sponsor
- Rutgers, The State University of New Jersey
Influenza, Human
A Study to Evaluate the Immunogenicity and Safety of Seqirus Quadrivalent Influenza Vaccine (QIV) in a Pediatric Population 6 Months Through 59 Months of Age.
This is a study to assess the immune (antibody) response and safety of a Seqirus split virion, inactivated Quadrivalent Influenza Vaccine (Seqirus QIV), in comparison with a US licensed 2016/2017 Quadrivalent Influenza Vaccine…
- Trial name
- NCT02914275
- Testing
- Seqirus Quadrivalent Inactivated Influenza Vaccine, Comparator Quadrivalent Inactivated Influenza Vaccine
- Where
- 39 sites in United States
- Volunteers
- 2,250 people, healthy volunteers welcome
- Sponsor
- Seqirus
Influenza
Immunogenicity and Safety of Fluzone® Quadrivalent, Southern Hemisphere 2015 Formulation (Intramuscular Route)
The aim of the study was to assess the immunogenicity and safety of Fluzone Quadrivalent influenza vaccine Southern Hemisphere (SH) 2015 formulation in participants aged 18 to 60 years as well as in participants 61 years or…
- Trial name
- NCT03546192
- Testing
- Fluzone Quadrivalent Influenza Vaccine
- Where
- 3 sites in Philippines
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
MELAS Syndrome
Responses to Influenza Vaccine in Patients With Mitochondrial Disorders (MELAS)
This pilot clinical study evaluated the safety and metabolic responses to a licensed inactivated seasonal influenza vaccine (TIV) in mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes syndrome (MELAS)…
- Trial name
- NCT01831934
- Testing
- Fluzone®
- Where
- United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Stanford University
COVID-19
Immunogenicity and Safety Study of Self-amplifying mRNA COVID-19 Vaccine Administered With Influenza Vaccines in Adults
This is a multicenter, observer-blind, randomized, controlled phase 3 study to evaluate the immunogenicity, reactogenicity, and safety of an investigational self-amplifying RNA COVID-19 vaccine (ARCT-2303) administered…
- Trial name
- NCT06279871
- Testing
- ARCT-2303, Influenza vaccine, Influenza vaccine, adjuvanted
- Where
- 29 sites in Australia, Costa Rica and 2 more
- Volunteers
- 1,514 people, healthy volunteers welcome
- Sponsor
- Arcturus Therapeutics, Inc.
Immune Response to Influenza Vaccine, Influenza A Virus Infection
Randomized Study of Immune Response to Licensed Influenza Vaccines in Children and Adolescents
The purpose of this study is to assess the serologic and cell-mediated immune response to licensed live attenuated influenza vaccine (LAIV) and inactivated influenza vaccine (IIV) in children 5-17 years old.
- Conditions
- Immune Response to Influenza Vaccine, Influenza A Virus Infection, Influenza B Virus Infection
- Trial name
- NCT02250274
- Testing
- LAIV, IIV
- Where
- United States
- Volunteers
- 131 people
- Sponsor
- Marshfield Clinic Research Foundation
Influenza
Study to Evaluate the Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in Children
The objective of this study is to evaluate the immunogenicity and safety of GSK Biologicals' investigational vaccine GSK2340272A in children aged between 3 and 17 years.
- Trial name
- NCT00972517
- Testing
- GSK investigational vaccine GSK2340272A
- Where
- 8 sites in Germany
- Volunteers
- 245 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
COVID-19, Influenza A
MGC Health COVID-19 & Flu A+B Home Multi Test Usability Study
The purpose of this study is to evaluate the usability of the MGC Health COVID-19 \& Flu A+B Home Multi Test in home use.
- Conditions
- COVID-19, Influenza A, Influenza B
- Trial name
- NCT05732610
- Testing
- MGC Health COVID-19 & Flu A+B Home Multi Test, MGC Health COVID-19 & Flu A+B Home Multi Test (2 to 13 y/o)
- Where
- United States
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Medical Group Care, LLC
Seasonal Influenza
A Study of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults
The purpose of this study is to measure the safety and the immune response to 3 next-generation influenza vaccine candidates (mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1) compared with influenza vaccine candidate mRNA-1010 controls…
- Trial name
- NCT05827068
- Testing
- mRNA-1011.1, mRNA-1011.2, mRNA-1012.1
- Where
- 22 sites in United States
- Volunteers
- 698 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
Influenza, Vaccines Adverse Reaction
Surveillance for Adverse Events Following Influenza Immunization
Influenza vaccines are continuously modified to adjust to the virus antigenic shifts or drifts, and its safety profile may vary.
- Trial name
- NCT01318876
- Where
- 7 sites in Canada
- Volunteers
- 7,645 people, healthy volunteers welcome
- Sponsor
- PHAC/CIHR Influenza Research Network
Influenza
Annual Study to Investigate Inactivated Subunit Influenza Vaccine Due to New Virus Strains for the Southern Hemisphere 2015 Season
Influenza (flu) viruses change continuously, therefore also the parts of viruses used in influenza vaccines can vary from year to year.
- Trial name
- NCT02381418
- Testing
- Trivalent influenza subunit vaccine Influvac
- Where
- Australia
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Abbott